Core Viewpoint - The company expects a significant increase in net profit attributable to equity holders, projecting over 240 million yuan by 2025, which represents a year-on-year growth of approximately 139.4% compared to 100 million yuan for the year ending December 31, 2024 [1] - Revenue is anticipated to exceed 1.05 billion yuan, reflecting a year-on-year increase of about 34.6% from 780 million yuan for the year ending December 31, 2024 [1] Group 1 - The improvement in performance is driven by three main factors: strong domestic sales growth of flagship products, including the Qilin blood flow guiding device, neurovascular guide wires, UltraFree drug-eluting PTA balloon dilatation catheters, and Swan venous intraluminal radiofrequency closure catheters [1] - International sales have more than doubled year-on-year [1] - The company has maintained a relatively stable gross margin while continuously improving operational efficiency [1]
归创通桥：预计2025年净利润超2.4亿元 多款旗舰产品的国内销售持续强劲增长